58 results about "M2 phenotype" patented technology

The invention discloses a preparation method and application of a novel hybrid extracellular vesicle. According to the invention, vesicles derived from endothelial cells and neutrophil cells are combined with deferoxamine, and a biological mixed nano vesicle platform (DFO (HEVS)) is developed to solve the problem of diabetes wound healing. According to the dual-targeting system, DFO is accurately delivered to a wound part by utilizing CXCR4 mediated endothelial cell homing and beta2 integrin dependent inflammation tropism, DFO (at) HEVs activates and recovers vascular regeneration through HIF-1alpha / VEGF, ferroptosis is inhibited through Nrf2 / GPX4 signal transduction, macrophages are reprogrammed into a repair promoting M2 phenotype, and oxidative stress-inflammation-ferroptosis circulation is effectively broken.

The invention belongs to the field of traditional Chinese medicines, and particularly relates to an inhalation type pharmaceutical composition for treating inflammatory respiratory diseases and a preparation method thereof. The inhalation type pharmaceutical composition comprises an active component and a nano-liposome, and mannose is modified on the surface of the nano-liposome; the active ingredients comprise bulbus fritillariae cirrhosae total alkaloids and platycodin D; the nano-liposome is prepared from the following raw materials: phospholipid, cholesterol and cholesterol-polyethylene glycol 1000-mannose ester. The liposome can be specifically recognized by a mannose receptor highly expressed on the surface of alveolar macrophage through a surface-modified mannose ligand, so that the receptor-mediated endocytosis is started, and the wrapped bulbus fritillariae cirrhosae total alkaloids and platycodin D are efficiently introduced into cells. The inhaled pharmaceutical composition of the present invention collectively pushes macrophages from a pro-inflammatory M1 phenotype to a repairable M2 phenotype. Therefore, the overall curative effect of the combination of the two components is far better than that of the independent use of any component.

The invention is applicable to the field of new biomedical materials, and provides an antibacterial and immunoregulation hydrogel and a preparation method and application thereof, the hydrogel comprises oDex, EPL, TA and Fe < 3 + >, and three hydrogels with antibacterial, antioxidant, anti-inflammatory and immunoregulation functions can be obtained based on Schiff base bonds of oDex and EPL, ionic bonds and hydrogen bonds of TA and EPL and coordination of TA and Fe < 3 + >. The hydrogel has the advantages of being easy to operate, low in price and the like. The hydrogel has a photothermal therapy (PTT) combined EPL and TA / Fe < 3 + > compound sterilization function. The hydrogel has high adhesion, can effectively inhibit release of oxidative stress (RONS) and inflammatory factors by releasing TA, promotes polarization of macrophages from a pro-inflammatory M1 phenotype to an anti-inflammatory M2 phenotype, and can effectively promote healing of mouse diabetic bacterial infected wounds.

The invention provides in-situ forming fluid bionic hydrogel as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The invention provides an injectable GelSSO / PDA (at) SDF fluid bionic niche, after in-situ photo-crosslinking, preferential and sustained release of PDA (at) SDF NPs initiates early signal amplification, which recruits EPCs and MSCs through an SDF-1 alpha / CXCR4 axis, promotes activation of the angiogenic vascular niche through an AKT signal, and repolarizes macrophages to a regenerated M2 phenotype. Subsequently, the gradual degradation of the bionic niche triggers the stable release of SSO, and the later signal is further amplified to form an osteogenic niche with transcriptional activity, thereby maintaining the MAPK / ERK-mediated MSCs osteogenic differentiation. The fluid bionic niche can form a niche conforming to defects through photopolymerization, the local immune imbalance and endogenous progenitor cell recruitment are corrected in the early stage, then formation of new vessels and lamellar bones is promoted, and finally vascularization regeneration of diabetic skull defects is achieved.

The invention relates to the technical field of medicines, in particular to application of a mesenchymal stem cell exosome in preparation of a thermoplegia neuroprotective agent. It is found through experiments that MSC-Exos can remarkably promote polarization conversion of microglial cells from a pro-inflammatory M1 phenotype to an anti-inflammatory M2 phenotype, and therefore damage, caused by heat stroke, to a central nervous system is relieved.

An in vivo and in vitro editing preparation method for CAR-MΦ targeting tumor stem cells, and a use thereof. The invention provides a chimeric antigen receptor-macrophage (CAR-MΦ) and a nano-carrier based on self-assembled nano-micelles, which can be applied to immunotherapy of glioma. According to the present invention, (PA)2 peptide nano-micelles loaded with CD133-CAR plasmids are constructed, and a citraconic anhydride-modified dextran, which is a group targeting macrophage specific target CD206, is adopted for modification. The carrier is used to realize CAR editing of macrophage in vivo and in vitro, so as to facilitate the re-education of tumor-related macrophage from an M2 phenotype to an M1 phenotype. At the same time, the surface markers of tumor stem cells are targeted to accurately target the tumor stem cells, phagocytize tumor cells, activate tumor immunity, remodel the tumor inhibition microenvironment and specifically kill brain glioma stem cells, thereby efficiently treating brain glioma.

The invention discloses nasal injection type baicalein hydrogel as well as a preparation method and application thereof. The preparation method comprises the following steps: dissolving carboxymethyl chitosan in water, stirring to form a uniform carboxymethyl chitosan solution, then adding a 4-formylphenylboronic acid / baicalein solution, and then continuously stirring until yellow transparent hydrogel is formed, namely the nasal injection type baicalein hydrogel is obtained. The hydrogel has self-healing ability and proper viscosity, can be adhered to the epithelium of the nasal cavity and is continuously released in the microenvironment of the nasal cavity, so that the brain entering efficiency of the baicalein is remarkably improved; neurotoxic oligomers formed by abnormal aggregation of alpha-syn can be reduced; neuroinflammation can be relieved by regulating and controlling phenotypic polarization of microglial cells M2; oxidative stress can be improved by removing excessive ROS, dopaminergic neuron apoptosis is reduced, and the compound can be used for treating Parkinson's disease and has a good application prospect.

The invention discloses bioactive glass composite hydrogel as well as a preparation method and application thereof. The bioactive glass composite hydrogel comprises a photo-crosslinking hydrogel matrix and magnesium-doped bioactive glass filled in the hydrogel, the photo-crosslinking hydrogel matrix is obtained by photo-curing and crosslinking methacrylic acid acylated protein; the magnesium-doped bioactive glass is a porous material. The magnesium-doped bioactive glass powder is doped into the hydrogel, so that the mechanical strength of the hydrogel can be remarkably enhanced, the bone repair activity of the hydrogel is remarkably improved compared with that of existing bioactive glass composite hydrogel, specifically, the expression of osteogenic differentiation related genes (BMP2, COL1, OPN and RUNX2) can be up-regulated, MPs can be induced to be polarized to M2 phenotype, the expression of M1 phenotype genes can be inhibited, and the bone repair activity of the hydrogel is remarkably improved. The polypeptide has excellent osteogenesis regulation and control performance and immune regulation capability.

The invention discloses an engineered exosome of LTH peptide modified miR-146a-5p and application, the core component of the medicine is the engineered exosome, and the engineered exosome is constructed by the following method: miR-146a-5p mimic infected human renal tubular epithelium HK2 cells with nucleotide sequences shown as SEQ ID NO.1-SEQ ID NO.2 are cultured and screened, the exosome rich in miR-146a-5p is separated from the culture supernatant of the cells, and the exosome rich in miR-146a-5p is obtained. Then, the kidney targeting peptide LTH is modified on the surface of the exosome. The invention reveals that HNRNP M protein is a key molecule for regulating and controlling miR-146a-5p to be sorted and enter the exosome for the first time, and verifies that the engineered exosome can be efficiently enriched in kidney, and by delivering miR-146a-5p to target IRAK1 gene in macrophage and inhibiting TRAF6 / IKK / NF-kappa B inflammation signal pathway, the macrophage is promoted to be polarized to a repairable M2 phenotype, so as to realize the purpose of improving the activity of the miR-146a-5p. And finally, the kidney injury induced by the calcium oxalate crystal is effectively relieved. The medicine has the advantages of clear mechanism, strong targeting property, good biocompatibility and the like, provides a brand new immunoregulation treatment strategy for renal injury, and has a wide clinical application prospect.

The invention belongs to the field of biological medicine, and particularly relates to a medicine for promoting microglial cell M2 type polarization and application of the medicine. The drug provided by the invention contains Densiflorol B. The drug provided by the invention has the advantages that the drug effect is good; the medicine can promote M2 type polarization of microglial cells, and has protection and repair effects on damaged nerves.

The invention belongs to the field of gene engineering, and particularly relates to a construction method of a gene engineering strain for producing glucosamine, a product and application. According to the method, intestinal probiotics with colonization ability are taken as an original strain, and multi-round CRISPR-Cas9 and Red homologous recombination technology combined transformation is carried out: on the basis of knockout of manX, ptsG is knocked out, a gna1 gene cluster derived from saccharomyces cerevisiae is inserted, then nagE is knocked out, and glmS driven by a strong promoter is inserted. In cell co-culture, the strain can safely and effectively promote phenotype transformation of a murine microglial cell line from BV2 to M2. In an animal model, the strain can colonize intestinal tracts in a short time and produce glucosamine, the effective concentration duration of glucosamine in serum is remarkably prolonged, inflammation is continuously inhibited, and the effect of enhancing immunity is achieved. And the strain does not have obvious toxicity, so that a new way is opened up for treating inflammatory diseases of engineering probiotics.

Compositions of matter and therapeutic methods for preventing, reducing, or reversing liver pathologies. Autologous pluripotent stem cells for generating monocytes or macrophages that are capable of suppressing liver failure. Methods of administering monocytes that are engineered or induced to facilitate hepatic regeneration. Hepatogenic cells such as monocytes are generated from induced pluripotent stem cells. Hepatogenic cells can be generated by overexpression of one or a plurality of factors associated with an M2 phenotype in pluripotent stem cell-derived monocytes such as signal transducer and activator of transcription 6 (STAT6) and transforming growth factor-beta. Hepatogenic monocytes can be generated in an environment that simulates liver injury.

The invention discloses a compound capable of treating skin wounds and a preparation method and application of the compound, relates to the field of skin wound healing, and aims to solve the problems that in the prior art, photo-thermal treatment cannot be compatible with sterilization and weak tissue damage, and sanshool is unstable and easy to degrade, the adopted technical scheme is that PCM is used for loading sanshool and TIIG NPs. Light energy can be converted into heat energy under the mild photo-thermal condition, then phase change of the phase change material lipidosome is promoted, sanshool is released, physical sterilization and chemical sterilization effects are achieved at the same time, the obvious antibacterial effect on staphylococcus aureus and escherichia coli in vitro is achieved, macrophages can be promoted to be polarized to anti-inflammatory M2 phenotype, and the anti-inflammatory effect of the phase change material lipidosome is improved. The wound surface inflammation reaction is relieved. And the compound can completely inhibit the growth of bacteria, promote collagen deposition and realize complete healing of infected wounds within 12 days. The compound has efficient antibacterial and tissue repair functions and is good in biocompatibility.

This invention relates to the field of biomedical technology, specifically disclosing a biomimetic exosome derived from tumor cell membranes, its preparation method, and its applications. The preparation method of the biomimetic exosomes derived from tumor cell membranes provided by this invention includes the following steps: mixing LLC-derived cell membranes with doxorubicin and resveratrol solutions, and preparing biomimetic exosomes derived from tumor cell membranes by extrusion. The preparation method provided by this invention has advantages such as wide availability of raw materials, simple and controllable process, low technical threshold, and suitability for industrial-scale production. The biomimetic exosomes provided by this invention can effectively induce a specific immune response against tumor cells, achieving the purpose of inhibiting the progression of primary tumors and prolonging the survival of tumor-bearing mice. It can also promote the polarization of macrophages from a pro-tumor M2 phenotype to an anti-tumor M1 phenotype, laying a favorable foundation for the efficient implementation of subsequent immunotherapy and possessing broad application prospects.

The invention belongs to the technical field of biology, and particularly relates to application of SORBS2 in preparation of a medicine for treating melanoma. The technical problem to be solved by the invention is to provide a new choice for treating melanoma. The technical scheme of the invention is the application of SORBS2 protein in preparation of drugs for treating melanoma. The invention reveals that SORBS2 overexpression can inhibit growth and metastasis of melanoma, inhibit polarization of macrophages to M2 type and enhance anti-melanoma immune effect for the first time, and the SORBS2 overexpression can be used as a novel strategy for preparing and treating melanoma.

Methods according to certain embodiments include contacting a macrophage with a mannose receptor (CD206) binding agent in a manner sufficient to modulate activity of the macrophage. Methods for converting a phenotype of a macrophage from an M2 phenotype to an M1 phenotype are also provided. Methods for inhibiting growth of a CD206-expressing cell as well as methods for treating a subject for a neoplastic condition (e.g., cancer) or a condition associated with chronic inflammation are described. Immuno-modulating peptides suitable for use in the subject methods are also presented.

The invention discloses an M2 type microglial cell exosome and a preparation method and application thereof, and belongs to the technical field of biology, and the preparation method comprises the following steps: inoculating microglial cells at the density of 1 * 10 < 5 > cells / mL, treating the cells with IL-4 after the cells are adhered to the wall, inducing the cells to be polarized into an M2 phenotype, collecting a culture solution, and obtaining the M2 type microglial cell exosome M2-EXO through ultracentrifugation. After research, the M2-EXO is used for inhibiting neuroinflammation and improving sepsis-related encephalopathy of mice through miR-1949 mediated microglial cell phenotypic transformation. The research further finds that the M2-EXO can inhibit neuroinflammation through the miR-127-5p and improve the mouse schizophrenia caused by MK-801. Therefore, the invention also discloses an application of the M2-EXO and the miRNA thereof in treatment of sepsis-related encephalopathy and schizophrenia.

The application provides an amphiphilic functionalized D-form-alanine and a preparation method and application thereof, and a self-targeting carbon monoxide nanogenerator and a preparation method and application thereof, and belongs to the technical field of antibacterial materials. The application provides an amphiphilic functionalized D-form-alanine. The self-targeting carbon monoxide nanogenerator prepared by using the amphiphilic functionalized D-form-alanine changes the permeability of the outer membrane of the cell wall of gram-negative bacteria, is metabolically utilized by bacteria in a specific manner, generates CO under the action of light to kill bacteria, removes biofilms that are not easy to touch and are hidden in deep periodontal pockets, simultaneously relieves inflammation by inducing macrophages to polarize from an M1 phenotype to an M2 phenotype, further promotes alveolar bone regeneration, and avoids damage to normal tissues.

The invention relates to the field of biological medicines, in particular to application of a reagent for inhibiting CYBB expression of tumor-associated macrophages in preparation of medicines for treating liver cancer and sensitizing a PD-1 inhibitor. The invention reveals that CYBB + TAMs can be used as a marker of poor curative effect of PD-1 on treating liver cancer for the first time. Targeted CYBB can activate a cGAS-STING pathway by reprogramming tumor-related macrophages from an M2 phenotype (tumor promotion) to an M1 phenotype (tumor resistance), and then improve the tumor killing function of CD8 + T cells, thereby inhibiting the growth of liver cancer and promoting the curative effect of a PD-1 inhibitor on liver cancer. By inhibiting the CYBB gene, the growth of the liver cancer can be inhibited, and the sensitivity of the liver cancer to a PD-1 inhibitor can be improved, so that the curative effect of immunotherapy is improved.

The technology described herein is directed to monospecific anti-LILRB2 antibody constructs, as well as bispecific anti-LILRB2 antibody constructs that also inhibit targets such as PD-1 or VEGF. Such antibody constructs are capable of polarizing macrophages from an M2 phenotype to an M1 phenotype, activating T cells, and / or inhibiting growth of a cancer. Also described herein are nucleic acids and vector encoding such monospecific or bispecific anti-LILRB2 antibody constructs, cells expressing or in combination with such antibody constructs, and compositions comprising such antibody constructs, nucleic acids, vectors, or cells. The disclosure also relates to methods of modulating the immune or treating cancer using such monospecific or bispecific anti-LILRB2 antibody constructs.

The present application relates to a DNA drug, a gene targeting delivery system and its application in the treatment of lower extremity peripheral arterial disease. Specifically, the present application relates to a microcrystalline nanocarbon targeted drug delivery system and a plasmid containing human interleukin-4 gene loaded thereon. The delivery system comprises a matrix microcrystalline nanocarbon, and folate, polyethyleneimine and polyethylene glycol modified on the surface thereof. The matrix microcrystalline nanocarbon has a size of 5-20 nanometers, a crystallinity of >80%, a rich mesoporous structure, a high specific surface area and good biocompatibility. The present application also provides a preparation method of the system, which comprises the steps of synthesizing a matrix by pulse modulation radio frequency plasma enhanced chemical vapor deposition, surface functionalization modification and plasmid loading. After injection into the lower extremity muscle, the system can actively target the macrophages in the ischemic site, realize long-term expression of the IL-4 gene at the lesion site. It can effectively promote stable, mature functional angiogenesis by inducing macrophages to polarize to the repair M2 phenotype and regulating the OSM / GSNOR / ENG signal axis, thereby improving limb ischemia. The present application has important application value in the field of gene therapy for ischemic diseases, especially peripheral arterial disease and severe limb ischemia.

The invention discloses an application of Anti-TSLP (Transcriptional Stem Like Protein) in prevention or treatment of abdominal aortic aneurysm. The Anti-TSLP is an anti-TSLP (Transcriptional Stem Like Protein) monoclonal antibody. The application of Anti-TSLP as a monoclonal antibody drug in prevention or treatment of abdominal aortic aneurysm is found for the first time. By intraperitoneal injection of Anti-TSLP and neutralization of TSLP pro-inflammatory cytokines, macrophage M1 / M2 phenotype can be effectively regulated, macrophage-mediated inflammatory response can be regulated and controlled, abdominal aortic aneurysm can be relieved, and a potential treatment scheme is provided for precise treatment of patients with clinical abdominal aortic aneurysm.

The invention discloses application of radix trichosanthis polysaccharide to preparation of a medicine for regulating immunity and inhibiting postoperative recurrence of colorectal cancer. The radix trichosanthis polysaccharide is found to be capable of promoting M2 phenotype macrophages to be polarized to M1 phenotype, and has an immunoregulation function; meanwhile, proliferation of peripheral blood lymphocytes and spleen lymphocytes is promoted, the proportion of CD4 +, CD8 + and NK cells is increased, and the effect of enhancing immunity is achieved. Furthermore, the hydrogel CMOT prepared by taking the radix trichosanthis polysaccharide as the raw material has good biocompatibility in vitro and in vivo and has the qualified characteristic of hydrogel, and the CMOT hydrogel is found to have the effect of inhibiting the recurrence of the colorectal cancer when being applied to the resection part of the mouse colorectal cancer operation. Therefore, the radix trichosanthis polysaccharide hydrogel has the potential of becoming a postoperative wound dressing after cancer resection.

This invention relates to the field of biomedical technology, and discloses a 6mA modified single-stranded DNA sequence that specifically binds to the MYH9 protein and its application in the treatment of sepsis; the single-stranded DNA sequence is specifically bound to the MYH9 protein. N 6 A single-stranded DNA sequence modified with 6mA-methyladenine (nucleotide sequence shown in SEQ ID NO:1) exhibits a specific adenine (A) methylation at a specific position, which allows it to be specifically recognized and bound by the MYH9 protein. The binding specificity was verified in vitro / in vivo using EMSA, biotin DNA pulldown WB assays, and MYH9-DNA IP assays. This 6mA-modified single-stranded DNA, by binding to the MYH9 protein, activates the downstream JAK1-STAT6 signaling pathway, promoting macrophage polarization towards the M2 phenotype, inhibiting excessive inflammatory responses, improving survival rates, reducing pathological damage to spleen tissue, and ameliorhythmic symptoms such as weight loss and hypothermia in septic mice, thereby exerting an anti-septic effect. This effectively addresses the clinical pain points of existing non-specific anti-inflammatory therapies and possesses significant potential for drug development.

The invention discloses hydrogel for driving phenotypic conversion from M1 to M2 of macrophages and application of the hydrogel, the hydrogel comprises a matrix and an active component, the matrix is a chitosan quaternary ammonium salt-phenylboronic acid copolymer, and the active component is a fullerol-Apoptozole conjugate APamp formed by covalent coupling of fullerol and a small molecule inhibitor Apoptozole through an acylhydrazone bond; c60; the hydrogel is a fullerol-chitosan hydrogel which can respond to a hyperglycemia and oxidative stress wound microenvironment and can controllably release fullerol and a small molecule inhibitor Apoptozole to block a signal axis of mitochondria HSPA8-ROMO1, the three effects of antibiosis, antioxidation and immunoregulation can be integrated, and a precise treatment scheme is provided for chronic wounds of diabetes mellitus.

The application discloses a novel preparation method and application of hybrid extracellular vesicles. The application combines endothelial cell-derived and neutrophil-derived vesicles with deferoxamine to develop a biological mixed nano-vesicle platform (DFO@HEVs) to solve the problem of diabetic wound healing. The dual-targeting system utilizes CXCR4-mediated endothelial cell homing and beta2 integrin-dependent inflammatory tropism to accurately deliver DFO to the wound site, DFO@HEVs activate HIF-1alpha / VEGF to restore vascular regeneration, inhibit ferroptosis through Nrf2 / GPX4 signaling, and reprogram macrophages into a pro-repair M2 phenotype, effectively breaking the oxidative stress-inflammation-ferroptosis cycle.

This invention discloses a method, system, and apparatus for computer-aided drug screening based on temozolomide and ADAMTS1. This application is the first to discover that ADAMTS1 is significantly enriched in recurrent gliomas following temozolomide exposure; temozolomide strongly induces a stable senescence program, leading to excessive secretion of ADAMTS1. This senescence-induced protease coordinates significant changes in extracellular matrix composition. The remodeled microenvironment acts as a mechanobiochemical signaling agent, recruiting and polarizing host-derived myeloid cells to transform into the immunosuppressive M2 phenotype, thereby conferring chemotherapy resistance to residual glioma cells through paracrine signaling. This application reveals that the "senescence-ADAMTS1-ECM-M2" axis is a key non-cellular autonomous mechanism of temozolomide resistance. Targeting ADAMTS1-mediated matrix reprogramming can eliminate the immunosuppressive niche in gliomas and overcome chemotherapy resistance, showing broad application prospects.

The invention relates to application of a CD300LF small-molecule inhibitor, and belongs to the technical field of medicines. The CD300LF small-molecule inhibitor comprises temopril, and the small-molecule inhibitor temopril taking CD300LF as a target spot is screened from a small-molecule drug library approved by FDA through computer high-throughput virtual drug screening in combination with biological activity screening. The invention reveals that temopril can be used as a CD300LF small-molecule inhibitor, is specifically combined with CD300LF, induces tumor-related macrophages to be converted from an M2 phenotype to an M1 phenotype, enhances the phagocytosis of the macrophages on tumor cells, and shows remarkable inhibition capability on tumor growth in an in-vivo experiment for the first time. In addition, it is found that after temopril and an immune checkpoint inhibitor are combined for use, a remarkable synergistic anti-tumor effect can be generated. The temopril can be used as a potential immunotherapy drug, and is expected to provide an experimental basis and a candidate drug for clinical treatment and prevention of cancers.

This invention belongs to the field of biotechnology, specifically disclosing a cRGD peptide-functionalized extracellular vesicle derived from mesenchymal stem cells, its preparation method, and its applications. The extracellular vesicle surface is anchored to the cRGD peptide via membrane fusion technology, enabling active targeting and activation of microglia. The preparation method includes isolating and culturing mesenchymal stem cells, purifying natural vesicles by differential ultracentrifugation, and then co-incubating with DSPE-PEG-cRGD for membrane insertion modification. In vitro and in vivo experiments show that the vesicles can be efficiently taken up by activated microglia, delivering endogenous miRNAs, inhibiting the NF-κB pathway, and promoting the transformation of microglia from the M1 to the M2 phenotype. In a retinal ischemia / reperfusion injury model, intravitreal injection of the vesicles reduces retinal ganglion cell apoptosis, protects retinal structure and optic nerve integrity, and restores electroretinogram function. This invention can be used to prepare drugs to alleviate neuroinflammation caused by acute glaucoma.

The application discloses a preparation method of a 3D printing cerium hydroxyapatite bone repair scaffold material, and comprises the following steps: adding phenyl (2, 4, 6-trimethylbenzoyl) lithium phosphate salt powder into manganese-chelated deferoxamine grafted methylacryl gelatin, stirring, adding cerium hydroxyapatite nanowires which are surface-modified by citric acid, and stirring to obtain 3D printing slurry; and the 3D printing slurry is extruded by a 3D printer while being cross-linked by 365nm ultraviolet irradiation to obtain the 3D printing cerium hydroxyapatite bone repair scaffold material; the material has good biocompatibility, can promote vascularization and immune regulation, and can effectively regulate M2 phenotype differentiation of RAW264.7, so that more BMP-2 and PDGF-bb growth factors are secreted, osteogenesis differentiation and angiogenesis are promoted, and bone defect repair is promoted from the perspective of immune regulation.